13F Holdings
中文EN

MAZE Maze Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1842295 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-20.1%
TTM EPS YoY32.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-37.5%
ROA-32.4%
ROIC (approx.)-69.0%
Asset turnover—

Leverage & solvency

Liabilities / assets16.2%
Debt / equity0.09x
Current ratio14.14x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue—$167.50M
R&D expense$108.45M$83.50M
SG&A expense$34.45M$26.42M
Operating income-$142.90M$57.59M
Pretax income-$131.12M$53.40M
Income tax$0$1.17M
Net income-$131.12M$52.23M
EBITDA-$140.50M$60.88M
EPS (basic)-3.051.42
EPS (diluted)-3.051.25
Weighted avg. shares (diluted)42.98M2.73M
Balance sheet
Cash & equivalents$189.25M$197.90M
Short-term investments$152.67M—
Current assets$349.72M$201.67M
PP&E, net$5.04M$6.67M
Total assets$397.13M$240.54M
Current liabilities$22.56M$20.67M
Total liabilities$42.16M$43.64M
Shareholders' equity$354.97M-$311.18M
Shares outstanding49.34M2.45M
Cash flow statement
Operating cash flow-$111.94M$75.95M
Capital expenditure$794,000$1.15M
Free cash flow-$112.73M$74.81M
Investing cash flow-$170.96M-$1.15M
Financing cash flow$275.34M$92.85M
Depreciation & amortization$2.40M$3.30M
Stock-based compensation$16.40M$9.65M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.